Picture a senior med-tech director or clinical leader four years into their tenure: RSUs vesting every quarter, a growing 401(k), and a brokerage account that is now heavier in company stock than any single position they would have chosen deliberately. Last spring, following their advisor’s guidance, they sold enough shares to bring that concentration back down to a prudent percentage of their overall portfolio. Six months later, it is right back near where it started. They did not make a mistake. They followed the standard playbook: diversify a concentrated holding. What that conventional wisdom leaves out is what happens when the next quarterly tranche lands in the same account, and the one after that, for as long as they stay with the firm. Managing a one-time windfall is a single decision. On an ongoing executive vesting schedule, it is a decision that must be made repeatedly, on a calendar you do not control.

Why the Usual Advice Treats This as a One-Time Problem

Most financial guidance regarding concentrated stock assumes the holding expanded through a single event: a private company’s initial public offering, an inheritance, or an equity grant that fully vested years ago. In those scenarios, “diversifying” involves a single transaction, or a brief series of trades, and the issue is resolved. The position shrinks and remains balanced.

An active executive vesting schedule functions differently. As long as you remain employed, new shares arrive on a set schedule, typically vesting quarterly or annually, regardless of your previous rebalancing trades. Selling down to a target percentage this quarter does not stop the next vesting date from depositing more shares. If the stock has also appreciated, the position can climb back above your target allocation faster than your last sale reduced it. The initial rebalancing was effective, but it was not permanent because the source of the concentration continues uninterrupted.

Why Each Sale Gets Harder to Make, Not Easier

Two distinct factors complicate executing these quarterly sales. The first is psychological loss aversion: watching your company’s stock continue to rise after selling a portion can feel like a missed opportunity, even when rebalancing was the right move for your family’s overall risk profile. That feeling makes placing the next sale feel more difficult.

The second factor involves the underlying tax mechanics. When RSUs vest, the fair market value is taxed as ordinary wage income. Employers generally withhold at a flat federal supplemental wage rate of 22% on the first $1 million in a calendar year. For high-earning medical professionals, department heads, and corporate VPs whose actual federal marginal tax bracket is significantly higher than 22%, this flat withholding rate leaves a tax gap relative to what will actually be owed at filing time. That shortfall can look like extra cash remaining in the account post-vest, even though a portion is already owed to the IRS. Reinvesting or spending those funds elsewhere, rather than selling additional shares to cover the tax gap, leaves the company stock position larger than intended.

The withholding rate applied at vest is a statutory flat percentage, not a complete representation of your final tax liability. The two amounts rarely match once total household income moves beyond the 22% bracket.

So Is It Worth It for You?

If equity compensation represents a minor slice of your total investable net worth, or if your vesting schedule is nearing its final tranche without new grant refreshes, evaluating each vest individually may be a manageable approach for a situation that will resolve itself. However, the calculus changes for leaders who receive ongoing equity refreshers year after year. In that case, the stock position is not a temporary spike to correct. It is a continuous flow that refills your portfolio regardless of your past decisions.

A practical diagnostic: evaluate what percentage of your total investable assets currently sits in employer stock, rather than what you intend to sell eventually. If that percentage consistently drifts back toward the same high level a few months after a sale, the issue isn’t the size of any individual trade. It is that the decision is being made from scratch every single quarter.

An effective solution to consider is establishing standing sale instructions, often structured via a 10b5-1 trading plan or an automated sell-to-cover arrangement through your equity platform administrator. This transforms diversification from a recurring manual choice into an automated rule, allowing your strategy to run smoothly alongside a corporate vesting schedule.

The central question to explore with your financial planner isn’t whether to manage concentrated company stock, most established professionals already recognize the importance of risk management. The question is whether implementing a standing rule tied directly to your vesting calendar can maintain your target asset allocation automatically, removing the need to remake the same complex decision every time new shares vest.